IT vendor offers a package for compliance with DEA monitoring requirements
Suspicious Order Monitoring (SOMLink) tracks ordering history with statistical analysis of baseline activity
The Drug Enforcement Administration (DEA) turned their screws on several major wholesalers last year for failing to properly monitor “suspicious orders”—those that, by their frequency, size or source indicate that abuse of controlled substances might be going on. Under DEA rules (21 CFR Part 1301.74b), manufacturers and distributors must carry out some level of monitoring. For that purpose, SOMLink, from e-SupplyLink (Traverse City, MI), maintains a database of client ordering history, and then flags suspicious orders, which are supposed to be held up until a manual check is completed. The package includes a variety of statistical analytical tools to identify out-of-the ordinary ordering patterns, according to Ronald McCreery, sales manager.
The SOMLink package runs on a Windows operating system, and can be linked, via XML, to a client’s ERP system, warehouse management system (WMS) or EDI-based financial reporting systems, according ot the company. E-SupplyLInk has a decade’s experience as a developer of EDI transaction software, shipping-label generation and order fulfillment; its flagship product is called ComplyLink.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
